ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
29.97
0.26
(0.88%)
Closed July 21 4:00PM
29.99
0.02
(0.07%)
After Hours: 7:51PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
29.99
Bid
-
Ask
-
Volume
30,006,022
29.5501 Day's Range 30.00
25.20 52 Week Range 37.80
Market Cap
Previous Close
29.71
Open
29.89
Last Trade
24
@
30
Last Trade Time
Financial Volume
$ 897,104,173
VWAP
29.8975
Average Volume (3m)
36,923,145
Shares Outstanding
5,666,592,898
Dividend Yield
5.57%
PE Ratio
80.16
Earnings Per Share (EPS)
0.37
Revenue
58.5B
Net Profit
2.12B

About Pfizer Inc

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers includ... Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
New York, New York, USA
Founded
1970
Pfizer Inc is listed in the Pharmaceutical Preparations sector of the New York Stock Exchange with ticker PFE. The last closing price for Pfizer was $29.71. Over the last year, Pfizer shares have traded in a share price range of $ 25.20 to $ 37.80.

Pfizer currently has 5,666,592,898 shares outstanding. The market capitalization of Pfizer is $168.35 billion. Pfizer has a price to earnings ratio (PE ratio) of 80.16.

Pfizer (PFE) Options Flow Summary

Overall Flow

Bearish

Net Premium

-10M

Calls / Puts

118.18%

Buys / Sells

83.33%

OTM / ITM

35.00%

Sweeps Ratio

0.02%

PFE Latest News

Ericsson Reports 14% Profit Increase, UBS Downgrades Tesla Shares, Ozempic Linked to Reduced Dementia Risk

Ericsson AB (NASDAQ:ERIC) – Ericsson AB exceeded analysts’ expectations in the second quarter, benefiting from cost-cutting measures amid a challenging market. The Swedish company...

Pfizer Advances Development of Once-Daily Formulation of Oral GLP-1 Receptor Agonist Danuglipron

Clinical evaluation of several modified release once-daily formulations of danuglipron resulted in encouraging pharmacokinetic data for several candidates with one showing the most favorable...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
11.113.8434903047128.8830.6928.793531078529.52460097CS
42.248.0720720720727.7530.6927.073163597128.44901123CS
124.6618.397157520725.3330.6925.23692314528.14186761CS
261.966.9925080271128.0330.6925.23964316427.5467706CS
52-6.35-17.473858007736.3437.825.23658240029.22944692CS
156-10.1-25.193315041240.0961.7125.23043675040.19705582CS
260-13.26-30.658959537643.2561.7182987808738.88320783CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SERVServe Robotics Inc
$ 7.51
(185.55%)
266.26M
AUGXAugmedix Inc
$ 2.27
(147.71%)
24.14M
XCURExicure Inc
$ 0.5351
(76.02%)
14.02M
PSNLPersonalis Inc
$ 3.83
(56.33%)
22.8M
MDBHMDB Capital Holdings LLC
$ 10.675
(37.21%)
126.45k
SPWRSunPower Corporation
$ 0.6735
(-55.40%)
124.61M
HYZNHyzon Motors Inc
$ 0.149
(-47.54%)
23.63M
MEDSTRxADE Health Inc
$ 14.92
(-33.45%)
223.27k
SILOSilo Pharma Inc
$ 2.50
(-27.95%)
11.93M
KITTNauticus Robotics Inc
$ 0.0935
(-27.46%)
28.43M
SERVServe Robotics Inc
$ 7.51
(185.55%)
266.26M
SXTP60 Degrees Pharmaceuticals Inc
$ 0.2602
(5.77%)
226.82M
NVDANVIDIA Corporation
$ 117.93
(-2.61%)
217.11M
SQQQProShares UltraPro Short QQQ
$ 8.46
(2.79%)
188.2M
SPWRSunPower Corporation
$ 0.6735
(-55.40%)
124.61M

PFE Discussion

View Posts
Vexari Vexari 1 day ago
How does one know this

What test was used

Why Paxlovid
💩 1 🤡 1 🤪 1 🦃 1 🦤 1
axelvento axelvento 2 days ago
President Biden tests positive for Covid with mild symptoms, per White House, and has received first dose of Paxlovid
👍️0
Vexari Vexari 3 days ago
It's a mind thing

Without having to think
💩 1 🤡 1 🤪 1 🦤 1 🪞 1
Monroe1 Monroe1 3 days ago
Giving Planned Obsolescence a new replacement.
👍️0
Vexari Vexari 3 days ago
The basic premise of wellness

Is being turned on its head

Perception of wellness

While making one sick

No need to worry

Have something for that

Another form of

Predictive programming
👍️0
Monroe1 Monroe1 4 days ago
https://mypatriotsnetwork.com/big-pharma-protections-under-attack-as-americans-fight-back/?utm_name=Id
👍️0
Monroe1 Monroe1 4 days ago
I was hoping it would dip to 22 and would have bot a few to flip. I think it will probably climb but there are head winds and lots of analysts are doubting the latest strategies.
👍️0
Monroe1 Monroe1 4 days ago
for certain. will be waiting.
👍️0
Vexari Vexari 5 days ago
What happens when the scam is revealed

Totally against the grain

But true
👎️ 1 💩 1 🤡 1 🤪 1 🦤 1
axelvento axelvento 5 days ago
I agree 1000%

Stock Dividend $$$$$$$$$
👍️0
Nebuchadnezzar Nebuchadnezzar 5 days ago
good news from their latest acquisition, or the accretive benefits of it or a dividend hike or stock buyback announcement

also a safe haven money rotation play as rates come down a little

PFE has been one of the worst trading stocks in months, i think it truly bottomed out

$25-27 was a great buy area imo
👍️0
Vexari Vexari 5 days ago
What is the control mechanism

That makes it so
👎️ 1 💩 1 🤡 1 🤪 1 🪳 1
Nebuchadnezzar Nebuchadnezzar 5 days ago
if UNH can surge $33 in one day, PFE can surge $2-$4 in one day
👍️0
Monroe1 Monroe1 5 days ago
It has been a year since that happened. I predicted this climb which is why I covered my shorts. 35 would be a good place to short again but most likely there will be set backs before reaching it. Bares watching,,, or should I say bears watching. Too bad this isn't an honest company.
👍️0
Vexari Vexari 5 days ago
Still trying to figure out

What is wrong with

The human immune system

Where it would need

So much help

Poisoning aside
💩 1 🗑️ 1 🤡 1 🤪 1 🦤 1
Nebuchadnezzar Nebuchadnezzar 5 days ago
PFE going back to $35
👍️0
Vexari Vexari 1 week ago
Us and Them

Pink Floyd
💩 1 🤡 1 🤮 1 🦤 1
axelvento axelvento 1 week ago
THE WRITING IS ON THE WALL
👍️0
Vexari Vexari 1 week ago
Rather than cite

It would be nice

To give an explanation

Have any of one's own words

To go behind what one posts

Curious
👎️ 1 💩 1 🤡 1 🦤 1 🪳 1
Monroe1 Monroe1 1 week ago
If you are long....why? Ok, I get it. But to continue is rubber stamping the company that killed your family and fellow citizens of the world.
Even Redfield finally admits it. "Redfield went further, admitting that the spike protein produced by mRNA vaccines is “toxic to the body” and triggers “a very strong pro-inflammatory response.”

https://childrenshealthdefense.org/defender/robert-redfield-mrna-covid-vaccine-risk/?utm_id=20240712
👎️ 1 💩 1 🗑️ 1 🦤 1
Monroe1 Monroe1 1 week ago
Well maybe https://www.fiercebiotech.com/biotech/pfizers-obesity-pill-news-leaves-analysts-wanting-biotech-investors-cheering?oly_enc_id=4924G0643390I0A
👍️0
Trend-Setter Trend-Setter 1 week ago
https://www.zacks.com/stock/news/2300964/the-zacks-analyst-blog-highlights-danaher-morgan-stanley-pfizer-elite-pharmaceuticals-and-oil-dri
👍️0
axelvento axelvento 1 week ago
https://www.biospace.com/article/pfizer-moves-forward-with-obesity-pill-plans-dose-optimization-studies-this-year/
👍️ 1 😀 1
Vexari Vexari 1 week ago
May the space
Be with you
💤 1 💩 1 🤡 1 🤪 1 🦤 1
axelvento axelvento 1 week ago
“Obesity is a key therapeutic area for Pfizer, and the company has a robust pipeline of three clinical and several preclinical candidates," said Pfizer's chief scientific officer, Mikael Dolsten.

"The most advanced of them, danuglipron, has demonstrated good efficacy in a twice-daily formulation, and we believe a once-daily formulation has the potential to have a competitive profile in the oral GLP-1 space."
👍️ 2 😀 1
Monroe1 Monroe1 1 week ago
The patent lawsuit in Germany will chop Pfizer down to size if this doesn't work out in their favor. This bears paying close attention.
😎 1
Vexari Vexari 1 week ago
For what ails humanity

Proverbial

Hamster wheel

Until a cure

With what they've got

Keep on running

While adding on

Never ending cycle

None of it is good
👍️ 1 👎️ 1 💩 1 🤡 1 🤪 1 🦤 1
Monroe1 Monroe1 1 week ago
TÜBINGEN, Germany/BOSTON, USA – July 11, 2024 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced the latest trial dates for its ongoing patent litigation against Pfizer/BioNTech in multiple geographies including the U.S., UK and Germany.



The U.S. trial against Pfizer/BioNTech will take place on March 3, 2025, before the U.S. District Court of the Eastern District of Virginia. A previously issued court recommendation to stay the proceedings for all 10 U.S. patents was withdrawn. The recommendation had followed a motion by Acuitas Therapeutics to intervene, sever and stay proceedings based on co-owner and co-inventorship claims. It was resolved after both companies reached a settlement in April 2024, which provided Acuitas licenses to several patents, including three out of four disputed U.S. patents. These three patents have been withdrawn from the U.S. patent litigation against Pfizer/BioNTech. In return, Acuitas acknowledges that CureVac is the sole owner of the disputed patents.



Litigation in Europe will continue March 25, 2025, with a hearing on the validity of EP 3 708 668 B1 (split poly-A tail technology), before the Opposition Division of the European Patent Office. The infringement action in relation to this patent was previously suspended pending the validity determination by the European Patent Office. In the German patent litigation against Pfizer/BioNTech, the settlement with Acuitas Therapeutics led to the withdrawal of two utility models covering equivalent claims to the three patents withdrawn in the United States. As previously announced, a hearing before the infringement court of Düsseldorf covering the European patent EP 4 023 755 B1 (split poly-A tail technology) and the utility model DE 20 2021 004 130 U1 (COVID-19 vaccine design), is scheduled for September 10, 2024.



Furthermore, a trial in the UK has started on July 10, 2024. It is based on a declaration of non-infringement and request for revocation by Pfizer/BioNTech in the UK for the two CureVac patents EP 3 708 668 B1 and EP 4 023 755 B1 (split poly-A-tail technology). CureVac counterclaimed for infringement. A judgement is expected later in 2024. The trial for the further involved patent EP 1 857 122 B1 (G/C enrichment technology) will be set for a later time point.
👍️ 1
Monroe1 Monroe1 1 week ago
I hope the oral version has better efficacy than the Covid Paxlovid.
👍️0
Monroe1 Monroe1 1 week ago
Wonder if he was one of the lucky ones working at Pfizer who did not choose the jab? Could be he took that special jab not offered to the public similar to the ones offered to Pfizer employees over in Australia. Who knows what is he feeling or thinking. Could be he is suffering and wants to play hard with his blood money before his next infarction. Hard to say. For his sake I hope his conscious is clean and his health is good. Amen.
👍️0
ziploc_1 ziploc_1 1 week ago
I anticipate that there will be a market for those patients, who have reached a point, where they are ready to discontinue injections of weight loss meds...but still want to continue with an oral weight loss med.
👍️0
DewDiligence DewDiligence 1 week ago
There’s discussion of the Danuglipron news on the Biotech Values board today.
👍️0
ziploc_1 ziploc_1 1 week ago
Dolsten,at age 66 ,with estimated net worth at over $50 million, is unlikely to be looking for challenging new employment..
👍️0
DewDiligence DewDiligence 1 week ago
But the PR did not say Dolsten was retiring, which it surely would have done if that were the case.
👍️ 1
ziploc_1 ziploc_1 2 weeks ago
"https://seekingalpha.com/news/4123562-pfizer-advances-development-of-once-daily-weight-loss-pill"

Pfizer's ORAL weight loss med IMO, would take significant market share away from the products, which are now on the market...since the competing meds need be taken by weekly INJECTIONS (even if the Pfizer med proves to be slightly less effective)...This would be especially true for patients, who disdain the nuisance and discomfort of injecting themselves on a weekly basis.
👍️0
ziploc_1 ziploc_1 2 weeks ago
'OUSTING' is probably the wrong word...Dolsten is 66 years old...and he probably thought it was time to retire and enjoy his fortune, achieved through being awarded millions of Pfizer shares over his 15 years with the company.
👍️ 1
Vexari Vexari 2 weeks ago
That is the question

A unique breed

Nonetheless
👍️ 1 💩 1 🤡 1 🤮 1 🦃 1 🦤 1
DewDiligence DewDiligence 2 weeks ago
PFE ousts CSO:

https://www.businesswire.com/news/home/20240709792921/en
👍️0
Monroe1 Monroe1 2 weeks ago
Who would consent knowing this?
https://petermcculloughmd.substack.com/p/a-pandoras-box-in-the-pharma-lab?publication_id=1119676&post_id=146401978&triggerShare=true&isFreemail=true&r=x7hm&triedRedirect=true
Well, PFE just shoots from the hip. No toxicology studies? OMG
Oh heck, they mean well. Guess I'll just bend over.

Knowing some of the facts that have been exposed....who in their right mind would invest in this company except to squeeze some profit from the pps movement?
👍️0
Monroe1 Monroe1 2 weeks ago
Hope they don't explode!
👍️0
Vexari Vexari 2 weeks ago
What happens next

Is

The question
💩 1 🤡 1 🤮 1 🦃 1 🦤 1
Vexari Vexari 2 weeks ago
It's all out there

~~~ Take the time ~~~
(49:02)

Ask questions

Mel K Show
💩 1 🗑️ 1 🤡 1 🤪 1 🦤 1
Vexari Vexari 2 weeks ago
Former Pfizer employee and Biotech Analyst Karen Kingston

~~~ “A lot of the dissenting opinions that were suppressed and ridiculed at the time ~~~
(1:10:33)

Have proven to be CORRECT
This includes, but is not limited to:

• COVID came from a lab?• Ivermectin worked?• Masks offered no benefit and were harmful?• Should have never kept kids out of school?• Natural immunity is better than vaccinated immunity?• Long COVID is often a symptom of long vax?• Hospitals murdered COVID patients?• COVID fatality rate and death count were highly inflated?• Unvaccinated were scapegoated for the failure of the shots?• Early treatment was suppressed to make way for a “vaccine”?• Risks of the jab were intentionally hidden from the public?• Vaccine mandates are wrong?• More shots = more risk of infection?• COVID shots are neither safe nor effectiveUSAFrontlineDoctors
💩 1 🗑️ 1 🤡 1 🤪 1 🦤 1
Vexari Vexari 2 weeks ago
Facts cannot be rationalized

To someone whose position

Is based on emotion
💩 1 🤡 1 🤪 1 🦤 1 🪳 1
Vexari Vexari 2 weeks ago
Noticing trend changes and pattern recognition

~~~ An epidemic of sudden deaths ~~~
(53:59)

Cause unknown

Perception vs Reality
👎️ 1 💩 1 🗑️ 1 🤡 1 🦤 1
Vexari Vexari 2 weeks ago
Free advertising a media collage

~~~ No one is safe ~~~
(11:24)

What to believe

Any help?

Philosophers-stone.info Pureblood
💩 1 🤡 1 🤮 1 🦃 1 🦤 1
girlfriend girlfriend 2 weeks ago
Yeah Josh told CNBC that anything under $30 was a gift.

Unfortunately if you look at his calls over the past year....some of them were really bad. Like Matterport, Dutch Bros, etc
👍️0
Nebuchadnezzar Nebuchadnezzar 2 weeks ago
Josh Brown told me to buy this ;)
👍️ 1
Monroe1 Monroe1 3 weeks ago
BARDA picking up Moderna off the floor. Will they save their PFE too? They funded the jab BioDefense development, gave it a cover story called PFE and Moderna who fought each other over the skimmed cream. So which side of the trade are you on? Truth and Liberty side or the corrupt substitute?
https://www.biospace.com/article/moderna-to-produce-bird-flu-vaccine-under-176m-barda-project-award/?_hsenc=p2ANqtz--DaFh4vOU_KJOhhBhQkYbnheU_gH0FQ52cDltJtNUqDLPc94oIRa-9-GmqzahCv2DS2HmSS2ES2uV2-D7wrm58PxHZrA&_hsmi=314119536
👍️0
DewDiligence DewDiligence 3 weeks ago
ACIP endorses MRK’s Capvaxive pneumococcal vaccine for certain groups—creating parity with PFE’s Prevnar-13 for adult market:

https://www.businesswire.com/news/home/20240627540619/en
• Adults 65 years of age and older who have not previously received a pneumococcal conjugate vaccine or whose previous vaccination history is unknown;

• Adults 19-64 years of age with certain underlying medical conditions or other risk factors who have not previously received a pneumococcal conjugate vaccine or whose previous vaccination history is unknown;

• Adults 19 years of age and older who have started their pneumococcal vaccine series with PCV13 (pneumococcal 13-valent conjugate vaccine) [PFE’s Prevnar-13] but have not received all recommended PPSV23 [MRK’s Pneumovax]…;

• Additionally, shared clinical decision-making is recommended regarding use of a supplemental dose of CAPVAXIVE for adults 65 years of age and older who have completed their vaccine series with both PCV13 [Prevnar-13] and PPSV23 [Pneumovax]. These ACIP recommendations are essentially the same as the CDC’s existing recommendations for PFE’s Prevnar-20, and hence they should allow MRK’s Capvaxive to gain a meaningful share in the adult portion of the pneumococcal vaccine market. PFE has had an overwhelming (>90%) share of this market in the US because MRK’s other conjugated pneumococcal vaccine, Vaxneuvance, received a less favorable recommendation from the CDC than PFE’s Prevnar-13.

Please see #msg-166441188 and #msg-172452293 for related info.
👍️0

Your Recent History

Delayed Upgrade Clock